New immune therapy aims to tame multiple sclerosis Flare-Ups
NCT ID NCT04530318
First seen Feb 20, 2026 · Last updated May 15, 2026 · Updated 10 times
Summary
This study tests a new treatment that uses a patient's own immune cells (dendritic cells) to help control relapsing-remitting multiple sclerosis (MS). About 45 adults with MS will receive this cell therapy along with their usual MS medications. The goal is to see if the combination can reduce brain lesions and MS relapses over 24 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSING REMITTING MULTIPLE SCLEROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Hospital Clínic de Barcelona
Barcelona, 08036, Spain
-
Hospital Moisés Broggi
L'Hospitalet de Llobregat, Barcelona, Spain
-
Hospital Universitari de Bellvitge
L'Hospitalet de Llobregat, Barcelona, Spain
-
Hospital de Sant Pau
Barcelona, Spain
-
Hospital del Mar
Barcelona, Spain
Conditions
Explore the condition pages connected to this study.